HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy
Synopsis
Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing.
Hims & Hers Health Inc. (HIMS) shares soared more than 52% in Monday’s pre-market trade after Novo Nordisk AS (NVO) dropped its patent infringement lawsuit against the company.
Novo Nordisk and Hims & Hers have also teamed up to offer access to Ozempic and Wegovy at the same affordable self-pay prices as other telehealth platforms.
Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing. Existing patients will have the opportunity to transition to FDA-approved medicines when their providers determine it clinically appropriate, the company said.
Novo shares were up more than 1% in Monday’s pre-market trade, while Hims & Hers shares were up around 48% at the time of writing. Retail sentiment around HIMS stock trended in the ‘extremely bullish’ territory on the platform.
Get updates to this story developing directly on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.